Avalon GloboCare Corp. (AVCO) News
Filter AVCO News Items
AVCO News Results
|Loading, please wait...|
AVCO News Highlights
- For AVCO, its 30 day story count is now at 4.
- Over the past 1 day, the trend for AVCO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- HA and NOV are the most mentioned tickers in articles about AVCO.
Latest AVCO News From Around the Web
Below are the latest news stories about AVALON GLOBOCARE CORP that investors may wish to consider to help them evaluate AVCO as an investment opportunity.
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that its ticker symbol will change on the NASDAQ Stock Exchange from “AVCO” to “ALBT” at the open of market trading on Thu
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Company to Begin Trading under New Symbol “ALBT” on November
Avalon GloboCare Corp (NASDAQ: AVCO) has agreed to acquire a 60% interest in Laboratory Services MSO LLC, a premier reference laboratory. What Happened: Total consideration for the acquisition will be $31 million, including $15 million in cash, $15 million in series B preferred shares, and $1 million payable after one year of the closing of the transaction The company paid a $5 million refundable cash advance with the signing of the definitive agreement. Additionally, Laboratory Services will ha
Investors in Avalon GloboCare (NASDAQ:AVCO) from five years ago are still down 72%, even after 32% gain this past week
Avalon GloboCare Corp. ( NASDAQ:AVCO ) shareholders will doubtless be very grateful to see the share price up 32% in...
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare, will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.Presentatio
Jointly with MIT, the Company also Submitted a New U.S. Patent Application for QTY Glucose TransportersFREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today provided an update regarding the Company’s intellectual property portfolio featuring its QTY protein code technology. The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications Reports plans to apply for additional patents related to QTY code applications jointly with MIT FREEHOLD, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new publication featuring the Company’s QTY protein code technology i
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer. The research demonstrates a novel method for quickly predicting the design of so-called “water-loving” or hydrop
Even after rising 13% this past week, Avalon GloboCare (NASDAQ:AVCO) shareholders are still down 73% over the past three years
It's nice to see the Avalon GloboCare Corp. ( NASDAQ:AVCO ) share price up 13% in a week. But the last three years have...